Literature DB >> 12714654

Human retinal molecular weight exclusion limit and estimate of species variation.

Timothy L Jackson1, Richard J Antcliff, Jost Hillenkamp, John Marshall.   

Abstract

PURPOSE: To determine the maximum size of molecule capable of freely diffusing across human retina, referred to as the retinal exclusion limit (REL), and the location of any sites of high resistance to diffusion. To assess the degree of interspecies variation in the REL of three animals commonly used to model human disease.
METHODS: Trephines of human neuroretina were mounted in a modified Ussing chamber. FITC-dextrans of various molecular weights (MWT) were dissolved in phosphate-buffered saline, and the rate of transretinal diffusion was determined over 24 hours with a spectrophotometer. The theoretical REL was calculated by extrapolating the linear relationship between the rate of diffusion and log(MWT). In separate experiments to determine the sites of barrier to diffusion, FITC-dextrans with a MWT greater than the calculated REL were applied to either the inner or outer retinal surface, processed as frozen sections, and viewed with a fluorescence microscope. Experiments to determine the REL were repeated in bovine, porcine, and rabbit retina.
RESULTS: The REL in human tissue was 76.5+/-1.5 kDa (6.11+/-0.04 nm). The inner and outer plexiform layers formed the sites of highest resistance to diffusion. The REL in pigs, cattle, and rabbits were 60 +/- 11.5, 78.5 +/- 20.5, and 86 +/- 30 kDa, respectively (5.68 +/- 0.45, 6.18 +/- 0.61, and 6.38 +/- 0.88 nm).
CONCLUSIONS: In humans, the inner and outer plexiform layers are sites of high resistance to the diffusion of large molecules, resulting in an REL of 76.5 kDa. There was only moderate interspecies variation in the REL of the animals studied, suggesting that they provide adequate models for the study of human transretinal macromolecular diffusion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12714654     DOI: 10.1167/iovs.02-1027

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  31 in total

1.  [Subretinal co-application of rtPA and bevacizumab for exudative AMD with submacular hemorrhage. Compatibility and clinical long-term results].

Authors:  J Hillenkamp; A Klettner; S Puls; F Treumer; J Roider
Journal:  Ophthalmologe       Date:  2012-07       Impact factor: 1.059

2.  Can ultrasound solve the transport barrier of the neural retina?

Authors:  Liesbeth Peeters; Ine Lentacker; Roosmarijn E Vandenbroucke; Bart Lucas; Joseph Demeester; Niek N Sanders; Stefaan C De Smedt
Journal:  Pharm Res       Date:  2008-07-23       Impact factor: 4.200

3.  Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina.

Authors:  Hyuncheol Kim; Shaun B Robinson; Karl G Csaky
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

4.  Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator.

Authors:  Jost Hillenkamp; Vladimir Surguch; Carsten Framme; Veit-Peter Gabel; Helmut G Sachs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-08-11       Impact factor: 3.117

Review 5.  Therapeutic antibodies in ophthalmology: old is new again.

Authors:  Charlotte Magdelaine-Beuzelin; Coralie Pinault; Gilles Paintaud; Hervé Watier
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

6.  Transfer of single dose of intravitreal injection of ranibizumab and bevacizumab into milk of sheep.

Authors:  Tugba Cakmak Argun; Ozlem Yalcin Tok; Levent Tok; Gulsen Yilmaz; Fatma Meric Yilmaz; Alime Gunes; Mehmet Argun; Osman Butuner
Journal:  Int J Ophthalmol       Date:  2017-07-18       Impact factor: 1.779

7.  Examination of barriers and barrier alteration in transscleral iontophoresis.

Authors:  Sarah A Molokhia; Eun-Kee Jeong; William I Higuchi; S Kevin Li
Journal:  J Pharm Sci       Date:  2008-02       Impact factor: 3.534

Review 8.  Recent perspectives on the delivery of biologics to back of the eye.

Authors:  Mary Joseph; Hoang M Trinh; Kishore Cholkar; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Deliv       Date:  2016-09-06       Impact factor: 6.648

9.  Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor.

Authors:  Yukio Sassa; Yasuaki Hata
Journal:  Clin Ophthalmol       Date:  2010-04-26

10.  FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.

Authors:  Hyuncheol Kim; Shaun B Robinson; Karl G Csaky
Journal:  Mol Vis       Date:  2009-12-16       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.